Literature DB >> 30697637

Irreversible Electroporation for Unresectable Hepatocellular Carcinoma: Initial Experience.

Naveen Kalra1, Pankaj Gupta2, Ujjwal Gorsi3, Harish Bhujade3, Shreedhara B Chaluvashetty3, Ajay Duseja4, Virendra Singh4, Radha K Dhiman4, Yogesh K Chawla4, Niranjan Khandelwal3.   

Abstract

PURPOSE: To evaluate the efficacy and safety of irreversible electroporation (IRE) in the treatment of unresectable hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: A retrospective study was conducted from September 2014 to June 2017. A total of 21 HCCs in 21 patients with cirrhosis were treated with IRE. There were eight subcapsular or exophytic, ten perivascular and three peribiliary tumors. The median tumor size was 26 mm (range 14-40 mm). The technical success of the procedure was recorded. Median follow-up, median time to local recurrence, median local tumor progression-free survival (PFS) and complications were recorded.
RESULTS: Technical success was achieved in all the patients. The median follow-up was 10 months (range 2-30 months). The median time to local recurrence and local tumor PFS were 4 months (range 3-4 months) and 7 months (range 3-30 months), respectively. The tumor-related factor that was significantly associated with local PFS was the size. Maximum tumor diameter < 25 mm was significantly associated with local tumor PFS (p = 0.045). Other parameters including tumor location, segmental portal vein thrombosis, baseline alpha-fetoprotein level and underlying etiology did not affect local tumor PFS. Complications were noted in nine patients and were classified as grades 1 and 2. No procedure-related mortality was encountered.
CONCLUSION: IRE is an effective treatment for ablation of small HCCs. Larger prospective studies with strict selection criteria will establish the safety and efficacy of IRE in the treatment of unresectable HCC in patients who cannot undergo thermal ablation.

Entities:  

Keywords:  Hepatocellular carcinoma; Irreversible electroporation; Radiofrequency ablation

Mesh:

Year:  2019        PMID: 30697637     DOI: 10.1007/s00270-019-02164-2

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  17 in total

1.  Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC: a systematic review and Bayesian network meta-analysis.

Authors:  Pankaj Gupta; Muniraju Maralakunte; Praveen Kumar-M; Karamvir Chandel; Sreedhara B Chaluvashetty; Harish Bhujade; Naveen Kalra; Manavjit Singh Sandhu
Journal:  Eur Radiol       Date:  2021-01-13       Impact factor: 5.315

2.  Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis.

Authors:  Pankaj Gupta; Muniraju Maralakunte; Sathya Sagar; Praveen Kumar-M; Harish Bhujade; Sreedhara B Chaluvashetty; Naveen Kalra
Journal:  Eur Radiol       Date:  2021-02-27       Impact factor: 5.315

Review 3.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23

4.  Percutaneous Cryoablation of Liver Tumors: Initial Experience from a Tertiary Care Center in India.

Authors:  Naveen Kalra; Pankaj Gupta; Tejeshwar Jugpal; Shailendra S Naik; Ujjwal Gorsi; Sreedhara B Chaluvashetty; Harish Bhujade; Ajay Duseja; Virendra Singh; Radha K Dhiman; Manavjit S Sandhu
Journal:  J Clin Exp Hepatol       Date:  2020-10-19

5.  Impact of needle positioning on ablation success of irreversible electroporation: a unicentric retrospective analysis.

Authors:  René Michael Mathy; Parham Tinoush; Ricardo Daniel da Florencia; Alexander Braun; Omid Ghamarnejad; Boris Radeleff; Hans-Ulrich Kauczor; De-Hua Chang
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

6.  In Vitro Study of Calcium Microsecond Electroporation of Prostate Adenocarcinoma Cells.

Authors:  Aleksander Kiełbik; Wojciech Szlasa; Olga Michel; Anna Szewczyk; Mounir Tarek; Jolanta Saczko; Julita Kulbacka
Journal:  Molecules       Date:  2020-11-19       Impact factor: 4.411

Review 7.  Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria.

Authors:  Yanzhao Zhou; Yi Yang; Bingyan Zhou; Zhengzheng Wang; Ruili Zhu; Xun Chen; Jingzhong Ouyang; Qingjun Li; Jinxue Zhou
Journal:  J Hepatocell Carcinoma       Date:  2021-06-21

Review 8.  Recent progress in pulsed electric field ablation for liver cancer.

Authors:  Zhen-Guo Liu; Xin-Hua Chen; Zu-Jiang Yu; Jun Lv; Zhi-Gang Ren
Journal:  World J Gastroenterol       Date:  2020-06-28       Impact factor: 5.742

Review 9.  Irreversible Electroporation For Liver Tumors: A Review Of Literature.

Authors:  Asim Tameez Ud Din; Ahsan Tameez-Ud-Din; Farooq Mohyud Din Chaudhary; Noman A Chaudhary; Khaleeq H Siddiqui
Journal:  Cureus       Date:  2019-06-25

10.  Investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers.

Authors:  Tomaz Jarm; Tadej Krmac; Ratko Magjarevic; Bor Kos; Helena Cindric; Damijan Miklavcic
Journal:  Biomed Eng Online       Date:  2020-11-16       Impact factor: 2.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.